Currently, the only marketed CXCR4 inhibitor is plerixafor (AMD 3100, a small-molecule drug) for stem cell mobilization in non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) patients. This evidence concerns the gene CXCR4 and Miyoshi myopathy.